A non-selective, peripheral anticholinergic agent (nsPAChA) selected from the group consisting of • quaternary ammonium nsPAChAs or sulfonium nsPAChAs represented by formula wherein - R is a radical selected from the group consisting of those of formulas (a)-(e) A being methyl and A' being (C 1 -C 4)alkyl or 2-fluoroethyl group or A and A' forming a 1,4-butylene or 1,5-pentylene chain, L being hydrogen or methoxy, Alk and Alk' each being (C 1 -C 4)alkyl and Y being a bivalent radical selected from the group consisting of 1,2-ethylene, 1,3-propylene, 1,4-butylene and 2-oxa-1,3-propylene; the corresponding counter ion being a pharmaceutically acceptable anion, - n and m, independently, are zero or 1, - X is a (C 2 -C 3)alkylene group, - R 1 and R 2 are each phenyl, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 2-thienyl and, when R is a radical (a), also each represents (C 1 -C 4)alkyl, - R 3 is H or OH or, only when R is a radical (a), also a COOAlk group, Alk being a (C 1 -C 4)alkyl group, • solifenacin and its pharmaceutically acceptable salts, • propiverine and its pharmaceutically acceptable salts, • oxyphencyclimine and its pharmaceutically acceptable salts, and • tolterodine and its pharmaceutically acceptable salts; in combination with an acetyl choline esterase inhibitor (AChEI) at a dose level from 1.5 to 4 times higher than a maximal tolerated dose of said AChEI for use in treatment of Alzheimer type dementia in a patient; wherein said AChEI is selected from the group consisting of tacrine, donepezil, rivastigmine, galantamine, and pharmaceutically acceptable salts thereof. • quaternary ammonium nsPAChAs or sulfonium nsPAChAs represented by formula wherein - R is a radical selected from the group consisting of those of formulas (a)-(e) A being methyl and A' being (C 1 -C 4)alkyl or 2-fluoroethyl group or A and A' forming a 1,4-butylene or 1,5-pentylene chain, L being hydrogen or methoxy, Alk and Alk' each being (C 1 -C 4)alkyl and Y being a bivalent radical selected from the group consisting of 1,2-ethylene, 1,3-propylene, 1,4-butylene and 2-oxa-1,3-propylene; the corresponding counter ion being a pharmaceutically acceptable anion, - n and m, independently, are zero or 1, - X is a (C 2 -C 3)alkylene group, - R 1 and R 2 are each phenyl, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 2-thienyl and, when R is a radical (a), also each represents (C 1 -C 4)alkyl, - R 3 is H or OH or, only when R is a radical (a), also a COOAlk group, Alk being a (C 1 -C 4)alkyl group, - R is a radical selected from the group consisting of those of formulas (a)-(e) A being methyl and A' being (C 1 -C 4)alkyl or 2-fluoroethyl group or A and A' forming a 1,4-butylene or 1,5-pentylene chain, L being hydrogen or methoxy, Alk and Alk' each being (C 1 -C 4)alkyl and Y being a bivalent radical selected from the group consisting of 1,2-ethylene, 1,3-propylene, 1,4-butylene and 2-oxa-1,3-propylene; the corresponding counter ion being a pharmaceutically acceptable anion, - n and m, independently, are zero or 1, - X is a (C 2 -C 3)alkylene group, - R 1 and R 2 are each phenyl, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 2-thienyl and, when R is a radical (a), also each represents (C 1 -C 4)alkyl, - R 3 is H or OH or, only when R is a radical (a), also a COOAlk group, Alk being a (C 1 -C 4)alkyl group, • solifenacin and its pharmaceutically acceptable salts, • propiverine and its pharmaceutically acceptable salts, • oxyphencyclimine and its pharmaceutically acceptable salts, and • tolterodine and its pharmaceutically acceptable salts;